Quantcast

Latest Demethylating agent Stories

2012-01-23 10:47:41

UT MD Anderson researchers expose molecular connection between inflammation, methylation Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer, scientists at The University of Texas MD Anderson Cancer Center report today in the advance online publication of the journal Nature Medicine. The team's connection of these two separate influences eventually may lead to better combination therapies for...

2010-06-10 13:16:13

The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time. Advanced ovarian cancer is often diagnosed too late for treatment to be...

2008-08-25 12:01:19

The Moffitt Cancer Center announced today that Dr. Alan List, Physician-in-Chief, was one of the key investigators in a VIDAZA (azacitidine) clinical trial (AZA-001) whose results the U.S. Food & Drug Administration (FDA) has approved to add to the drug's label. In May 2004, VIDAZA was the first drug approved by the FDA for the treatment of MDS. The AZA-001 study is the largest ever phase III; multi-center randomized trial involving higher-risk MDS patients. This study found that...

2008-08-22 12:00:16

The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients. Data from the AZA-001 trial was recently presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting and found that azacitidine nearly...

2008-08-21 09:00:22

Celgene Corporation (Nasdaq:CELG) today announced VIDAZA (azacitidine) received expanded U.S. Food and Drug Administration (FDA) approval to reflect new overall survival achieved in the AZA-001 survival study of patients with higher-risk myelodysplastic syndromes (MDS). This expanded indication supplements the 2004 FDA authorization of VIDAZA as the first therapy approved in the U.S. for the treatment of patients with all five French American British (FAB) subtypes of MDS. VIDAZA is also the...

2008-06-26 12:02:01

MethylGene has initiated a Phase II clinical trial evaluating MGCD0103, an isoform-selective histone deacetylase inhibitor product candidate, in combination with Vidaza, a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia. The study is a three-arm, randomized trial which will enroll up to 180 patients at cancer centers in North America and Europe. Charles Craddock, professor of haemato-oncology at University of Birmingham, UK, said:...

2008-06-25 09:01:48

MONTREAL, QUEBEC--(Marketwire - June 25, 2008) - MethylGene Inc. (TSX:MYG) announced today the initiation of a Phase II clinical trial (Trial 013) evaluating MGCD0103, an isoform-selective histone deacetylase (HDAC) inhibitor product candidate, in combination with Vidaza(R) (azacitidine for injection), a DNA demethylating agent, in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). The study is a three-arm, randomized trial which will enroll up to 180...

2006-11-21 03:00:23

BOULDER, Colo., and KYOTO, Japan, Nov. 21 /PRNewswire-FirstCall/ -- Pharmion Corporation and Nippon Shinyaku Co., Ltd today announced the completion of an exclusive license agreement for development and commercialization rights to Vidaza (azacitidine for injectable suspension) in Japan. Terms of the agreement were not disclosed. The agreement requires Nippon Shinyaku to pay both royalties and milestone payments to Pharmion upon the achievement of certain regulatory and sales milestones,...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'